Towards immunotherapy of pancreatic cancer

Gut

Volumn 44, Issue 6, 1999, Pages 767-769

  McKenzie, I F C ^a   Apostolopoulos, V ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CARBOHYDRATE ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LISTERIOLYSIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANNAN; MUCIN; PROTEIN P53; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CELL LYSATE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENDOSOME; HUMAN; LYSOSOME; MACROPHAGE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE SUBPOPULATION;

EID: 0033047054     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.44.6.767     Document Type: Review

References (33)

1. Kelly DM, Benjamin IS. Pancreatic carcinoma. Ann Oncol 1995;6:19-28.
2. Townsend ARH, Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Ann Rev Immunol 1989:7:601-24.
3. Germain RM, Marguiles DH. The biochemistry and cell biology of antigen processing and presentation. Ann Rev Immunol 1993;11:403-500.
4. Rammensee HG, Friede T, Stevanovic S. MHC ligand and peptide motifs: first listing. Anniversary review. Immunogenetics 1995;41:178-228.
5. Apostolopoulos V, Haurum JS, McKenzie IFC. MUC1 peptide epitopes associated with 5 different H2 Class I molecules. Eur J Immunol 1997;27:2579-87.
6. Apostolopoulos V, Chelvanayagam G, Xing PX, et al. Anti-MUC antibodies react directly with MUC1 peptides presented by class I H2 and HLA molecules. J Immunol 1998;161:767-75.
7. Mounier J, Ryter A, Coquis-Rondon M, et al. Intracellular and cell-to-cell spread of Listeria monocytogenes involves interaction with F-actin in the enterocyte-like cell line Caco-2. Infect Immun 1990;58:2822-31.
8. 2 immune responses. Proc Natl Acad Sci USA 1995;92:10128-32.
9. Brossay L, Burdin N, Tangri S, et al. Antigen-presenting function of mouse CD1: one molecule with two different kinds of antigenic ligands. Immunol Rev 1998;163:139-50.
10. Gendler S, Papadimitriou JT, Duhig T, et al. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 1988;263:12820-3.
11. Marjolijn JL, Ligtenberg MJL, Vos HL, et al. Episialin, a carcinoma-associated mucin is generated by a polymorphic gene encoding splice variants with alternating amino termini. J Biol Chem;265:5573-8.
12. Apostolopoulos V, Pietersz GA, McKenzie IFC. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 1996;14:930-8.
13. Gong J, Chen D, Kashiwaba M, et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 1998;95:6279-83.
14. Apostolopoulos V, Osinski C, McKenzie IFC. MUC1 cross-reactive Gal alpha(1,3)Gal antibodies in human switch immune responses from cellular to humoral. Nature Med 1998;4:315-20.
15. Jerome KR, Domenech N, Finn OJ. Tumor-specific CTL clones from patients with breast and pancreatic adenocarcinoma recognise EBV-immortalised B cells transfected with polymorphic epithelial mucin cDNA. J Immunol 1993;151:1654-62.
16. Peiper M, Goedegebuure PS, Linehan DC, et al. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. Eur J Immunol 1997;27:1115-23.
17. Alters SE, Gadea JR, Philip R. Immunotherapy of cancer. Generation of CEA specific CTL using CEA peptide pulsed dendritic cells. Adv Exp Med Biol 1997;417:519-24.
18. McCarty TM, Liu X, Sun JY, et al. Targeting p53 for adoptive T-cell immunotherapy. Cancer Res 1998;58:2601-5.
19. Gjersten MK, Saeterdal I, Beiske K, et al. Antigen-presenting function of human peritoneum mesothelial cells isolated from a pancreatic carcinoma patient after mutant Ras peptide vaccination. Cancer Immunol Immunother 1996;43:262-8.
20. Gjertsen MK, Bakka A, Breivik J, et al. Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. Int J Cancer 1996;6:450-3.
21. Gjertsen MK, Bakka A, Breivik J, et al. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet 1995;346:1399-400.
22. Friess H, Beger HG, Kunz J, et al. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial. Anticancer Res 1996;16:915-20.
23. Guo X, Friess H, Graber HU, et al. KAH expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Cancer Res 1996;56:4876-80.
24. Ho JJ, Kim YS. Serological pancreatic tumor markers and the MUC1 apomucin. Pancreas 1994;9:674-91.
25. Yamanaka Y, Friess H, Kobrin MS, et al. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol 1993;24:1127-34.
26. Motoo Y, Itoh T, Su SB, et al. Expression of pancreatitis-associated protein (PAP) mRNA in gastrointestinal cancers. Int J Pancreatol 1998;23:11-16.
27. Ohta T, Numata M, Tsukioka Y, et al. Neurotrophin-3 expression in human pancreatic cancers. J Pathol 1997;181:405-12.
28. Lee CS, Charalambous D. Immunohistochemical localisation of the c-fos oncoprotein in pancreatic cancers. Zentralbl Pathol 1994;140:271-5.
29. Berndt C, Haubold K, Wenger F, et al. K-ras mutations in stools and tissue samples from patients with malignant and nonmalignant pancreatic diseases. Clin Chem 1998;44:2103-7.
30. Maacke H, Kessler A, Schmiegel W, et al. Overexpression of p53 protein during pancreatitis. Br J Cancer 1991;75:1501-14.
31. Gansauge F, Gansauge S, Parker N, et al. CAM 17.1 a new diagnostic marker in pancreatic cancer. Br J Cancer 1996;74:1997-2002.
32. Pasanen PA, Eskelinen M, Partanen K, et al. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma. Anti-cancer Res 1993;13:1883-87.
33. Oremek GM, Eigenbrodt E, Radle J, et al. Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer. Anticancer Res 1997;17: 3031-3.